PDS Biotechnology, Inc. (NASDAQ:PDSB – Get Free Report) shares rose 0.8% during trading on Monday. The company’s shares traded as high as $3.94 and closed at $3.90. 195,832 shares were traded during trading, down 75% from the average trading volume of 770,141 shares. The stock closed at $3.87 earlier.
Analysts Set New Price Targets
Several brokerage firms have recently commented on PDSB. B. Riley lowered their price target on PDS Biotechnology from $11.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, June 12th. HC Wainwright reaffirmed their “buy” rating and set a $21.00 price target on shares of PDS Biotechnology in a research note on Wednesday, June 12th. Finally, Cantor Fitzgerald gave shares of PDS Biotechnology an “overweight” rating in a report on Thursday, May 9th. One investment analyst has assigned a sell rating to the company, and four have assigned a buy rating to the stock. According to MarketBeat.com, PDS Biotechnology currently has a consensus rating of a “moderate buy” with an average price target of $16.67.
Get the latest research report on PDS Biotechnology
PDS Biotechnology shares rose 0.8%
The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.45. Its 50-day moving average is $3.20 and its 200-day moving average is $4.06. The company has a market capitalization of $143.05 million, a price-to-earnings ratio of -2.87 and a beta of 1.91.
PDS Biotechnology (NASDAQ:PDSB – Get free report ) released its quarterly earnings report on Wednesday, May 15. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.07. Sell-side analysts expect PDS Biotechnology to post EPS of -$1.46 for the current quarter.
Institutional investor inflows and outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Kathleen S. Wright Associates Inc. acquired a new stake in PDS Biotechnology worth $28,000 in the first quarter. Tower Research Capital LLC TRC increased its stake in PDS Biotechnology by 530.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,046 shares of the company’s stock, valued at $45,000, after purchasing an additional 7,612 shares during the period. SG Americas Securities LLC acquired a new stake in PDS Biotechnology worth $52,000 in the fourth quarter. Inspirion Wealth Advisors LLC increased its stake in PDS Biotechnology by 1.4% in the second quarter. Inspirion Wealth Advisors LLC now holds 359,894 shares of the company’s stock, valued at $1,054,000, after purchasing an additional 4,917 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in PDS Biotechnology shares by 5.5% in the first quarter. Vanguard Group Inc. now holds 1,587,806 shares of the company’s stock, valued at $6,288,000, after acquiring an additional 82,135 shares during the period. Institutional investors hold 26.84% of the company’s stock.
About PDS Biotechnology
(Get your free report)
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company developing a pipeline of targeted cancer immunotherapies in the U.S. The company’s lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trials as a first-line treatment for recurrent/metastatic head and neck cancer and human papillomavirus-associated malignancies.
reference
Get PDS Biotechnology News and Ratings Daily – Enter your email address below to receive a concise summary of the latest news and analyst ratings on PDS Biotechnology and related companies every day with MarketBeat.com’s free email newsletter.
